MDSpire - Summary
Feature

From One Stem Cell to Millions of Cancer Killers

A three-step engineering strategy generates vast numbers of potent NK immune cells – potentially slashing the cost and scaling of cancer immunotherapy

  • April 1, 2026

  • 1 min

Share

Researchers from China have pioneered a novel method for mass-producing cancer-fighting immune cells by transforming a single stem cell into millions of natural killer (NK) cells, including highly targeted CAR variants. This innovative three-step process involves the expansion of CD34+ hematopoietic stem cells, differentiation through artificial organoid systems, and large-scale maturation. This technique not only elevates production efficiency by dramatically increasing yields but also substantially reduces production costs by minimizing viral vector requirements. Preclinical trials showed promising results in leukemia models, where CAR-NK cells significantly inhibited tumor growth and prolonged survival, suggesting potential for practical application in immunotherapy.

Original Source(s)

From One Stem Cell to Millions of Cancer Killers

  • April 1, 2026

Related Content

Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers

“For women with low-risk DCIS, these interim results are reassuring. There is currently no indication that active surveillance leads to worse early outcomes compared with immediate surgery. It’s impor...

Could Mass Spec Overcome the CAR T Solid Tumor Barrier?

Joey Sheff explains how proteomics is revealing targets, guiding CAR design, and predicting function in solid tumors.

  • April 1, 2026

  • 8 min
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...